AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20473630
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium supplement only)
Trial: 11753129
Drug: Bladder infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder infusion prior to catheter removal
Trial: 11753129
Drug: Ethanol‐glycine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol‐glycine in assessment of the absorption of irrigation fluid
Trial: 8839904
Drug: Tecogalan sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecogalan sodium (dosage levels: 125, 185, 240, 300, 390, 445, and 500 mg/m2) administered via single i.v. infusion every three weeks for 1 to 24 hours.
Trial: 8839904
Drug: Tecogalan sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecogalan sodium at the recommended phase II dose of 390 mg/m2 over 24 hours.
Trial: 6386932
Drug: Oral amrinone
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amrinone (113 +/- 33 mg three times daily)
Trial: 6386932
Drug: Oral amrinone
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amrinone
Trial: 6386932
Drug: Oral amrinone
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amrinone and Placebo
Trial: 31279306
Drug: Chemotherapy (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (in PENELOPE validation cohort)
Trial: 31279306
Drug: Bevacizumab-chemotherapy (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-chemotherapy (in AURELIA validation cohort)
Trial: 16306520
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg three times daily)
Trial: 8331205
Drug: Adinazolam mesylate
RxNorm normalized name: mesylate
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam mesylate immediate-release (CT) tablets (2 x 20 mg)
Trial: 8331205
Drug: Adinazolam sustained-release
RxNorm normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam sustained-release (SR) tablets (2 x 30 mg)
Trial: 31544802
Drug: Nutritional rehabilitation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation (n = 51)
Trial: 28363880
Drug: Web-based CPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based CPD program on providing oral hygiene care to stroke patients using TPB
Trial: 28363880
Drug: Web-based CPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based CPD program not specific to oral hygiene
Trial: 20977368
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg
Trial: 21709083
Drug: Linezolid 1200
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 1200 mg
Trial: 21709083
Drug: Linezolid 1200
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 1200 mg vs 600 mg
Trial: 28342632
Drug: Low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ticagrelor (90mg loading dose, then 90mg daily)
Trial: 28342632
Drug: Standard-dose ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ticagrelor (180mg loading dose, then 90mg twice daily)
Trial: 28342632
Drug: Clopidogrel (300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300mg loading dose, then 75mg daily)
Trial: 25620535
Drug: Etifoxine 150
RxNorm normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etifoxine 150 mg/day for 28 days
Trial: 25620535
Drug: Alprazolam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.5 mg/day for 28 days
Trial: 19067864
Drug: Corticosteroids (from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (from twice daily to one application every other day) combined with the studied cream (twice daily)
Trial: 19067864
Drug: Studied cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Studied cream (twice daily)
Trial: 19067864
Drug: Corticosteroids alone
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids alone (once or twice daily)
Trial: 14681620
Drug: External jugular
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External jugular vein (EJV) patch
Trial: 14681620
Drug: Polytetrafluoroethylene (PTFE)
RxNorm normalized name: polytetrafluoroethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytetrafluoroethylene (PTFE) patch
Trial: 9241289
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model with additional variable of need for labor augmentation.
Trial: 3584272
Drug: Oros drug
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oros drug delivery system (10/170 oxprenolol)
Trial: 3584272
Drug: Slow Trasicor
RxNorm normalized name: Slow Trasicor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Trasicor 160 mg orally
Trial: 3584272
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of pre‐equilibrated Oros systems
Trial: 23591255
Drug: Continuous-combined estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous-combined estradiol 1 mg/drospirenone 2 mg (E2D)
Trial: 21990176
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg, 3 times per day, orally
Trial: 18496952
Drug: Emergency bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency bypass for therapy refractory vasospasm (group II)
Trial: 12652173
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone loading for 24 hours
Trial: 10912543
Drug: Deflazacort (0.30+/‐0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (0.30+/‐0.03 mg/kg per day)
Trial: 1643923
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (20 mg)
Trial: 6228459
Drug: 3 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 micrograms heat-inactivated HBsAg vaccine
Trial: 6228459
Drug: 27 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 micrograms heat-inactivated HBsAg vaccine
Trial: 31376515
Drug: Artemisia afra
RxNorm normalized name: Artemisia vulgaris top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia afra extracts and compounds
Trial: 26332605
Drug: VRC01 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 intravenous (i.v.) infusion at 20 mg/kg
Trial: 26332605
Drug: VRC01 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 intravenous (i.v.) infusion at 40 mg/kg
Trial: 26332605
Drug: VRC01 subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 subcutaneous (s.c.) delivery at 5 mg/kg
Trial: 26332605
Drug: Placebo s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. given twice, 28 days apart
Trial: 26332605
Drug: VRC01 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (all doses)
Trial: 26332605
Drug: VRC01 (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (5-40 mg/kg i.v. range)
Trial: 19127261
Drug: WBRT+topotecan (RCT;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT+topotecan (RCT; 0.4 mg m(‐2) day(‐1) x 20)
Trial: 18379495
Drug: Antianginal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianginal and metabolic therapy
Trial: 15475832
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g oleic capsaicin-containing patches
Trial: 9769871
Drug: 2 nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 nucleoside analogues and a protease inhibitor
Trial: 2390434
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg mefloquine base weekly
Trial: 2390434
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg mefloquine base weekly
Trial: 27258249
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg FeLf (iron-lactoferrin complex) per day
Trial: 23791561
Drug: Neck manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck manual therapy
Trial: 23791561
Drug: Pragmatic, evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pragmatic, evidence-based treatment to the shoulder (control group)
Trial: 22995971
Drug: Warfarin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin anticoagulation with INR of 2 to 3
Trial: 16047062
Drug: Screening program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening program including free and total prostate specific antigen (PSA) and digital rectal examination (DRE)
Trial: 7874873
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin with responsive thromboplastin
Trial: 7874873
Drug: High-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose warfarin with high international sensitivity index thromboplastin
Trial: 2965227
Drug: Diuretics and
RxNorm normalized name: Low-ceiling diuretics and potassium-sparing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics and vasodilating agents (added where blood pressure was insufficiently controlled)
Trial: 2965227
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (beta-blockers and methyldopa)
Trial: 31955619
Drug: TNF‐α inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α inhibitor (Group A)
Trial: 31955619
Drug: Steroid (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (Group B)
Trial: 30343318
Drug: 2-L/kg/min high-flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L/kg/min high-flow nasal cannula (HFNC)
Trial: 30343318
Drug: 3-L/kg/min high-flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-L/kg/min high-flow nasal cannula (HFNC)
Trial: 21966753
Drug: Progesterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (100 mg/day IM)
Trial: 21966753
Drug: Estradiol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (2 mg of estradiol valerianate) plus progesterone (100 mg/day IM)
Trial: 12161047
Drug: Menorest 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest 50 microg/24 h (estradiol 4.3 mg) and Gestapuran 2.5 mg (medroxyprogesteron) daily
Trial: 10583115
Drug: 10 p.p.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 p.p.m. nickel concentration in water for 10 min daily for the first week, followed by 100 p.p.m. nickel concentration for the second week
Trial: 31536101
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg once daily (n=3023)
Trial: 31536101
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 to 4 mg once daily (n=3010)
Trial: 24524204
Drug: Daily Sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sedation Interruption (DSI) in combination with protocolized sedation
Trial: 22871933
Drug: Zilpaterol HCl
RxNorm normalized name: zilpaterol
DrugBank: Zilpaterol (DB11479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilpaterol HCl (8.33 mg/kg DM)
Trial: 22871933
Drug: Zilpaterol HCl
RxNorm normalized name: zilpaterol
DrugBank: Zilpaterol (DB11479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilpaterol HCl (8.33 mg/kg DM) with 148 DOF
Trial: 20298254
Drug: 1,064‐nm Q‐switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,064‐nm Q‐switched neodymium-doped yttrium aluminum garnet (QS‐Nd:YAG) laser treatment
Trial: 20298254
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment (2% hydroquinone)
Trial: 11932276
Drug: Flaxseed (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40 g daily for 3 months)
Trial: 11932276
Drug: Wheat-based comparative
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat-based comparative control regimen (40 g daily for 3 months)
Trial: 9795409
Drug: BMT (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMT (bismuth subsalicylate 600 mg t. i. d. for 28 days, metronidazole 400 mg t. i. d. and tetracycline 500 mg q. i. d. for ten days)
Trial: 9795409
Drug: OA (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA (omeprazole 40 mg o. d. and amoxicillin 750 mg q. i. d. for 14 days)
Trial: 9795409
Drug: OC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC (omeprazole 40 mg o. d. and clarithromycin 500 mg b. i. d. for 14 days)
Trial: 9795409
Drug: OT (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OT (omeprazole 40 mg o. d. and tetracycline 500 mg q. i. d. for 14 days)
Trial: 9795409
Drug: OMC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (omeprazole 40 mg o. d., metronidazole 400 mg t. i. d. and clarithromycin 250 mg b. i. d. for seven days)
Trial: 8578768
Drug: DV‐7751a 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DV‐7751a 100 mg
Trial: 8578768
Drug: DV‐7751a 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DV‐7751a 200 mg
Trial: 8578768
Drug: DV‐7751a 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DV‐7751a 400 mg
Trial: 8578768
Drug: DV‐7751a 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DV‐7751a 800 mg
Trial: 421671
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg xipamide daily
Trial: 421671
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg xipamide daily
Trial: 30883864
Drug: LSD (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (100 μg)
Trial: 24079847
Drug: Preparation intervention
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation intervention involving practice and feedback with cross-examination questions
Trial: 19781211
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg (high dose)
Trial: 19781211
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg (low dose)
Trial: 11059437
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus bi‐weekly automated assessment and self‐care education calls with telephone follow‐up by a nurse educator
Trial: 8358980
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of methotrexate (2.5mg oral daily doses, totaling 15 mg weekly)
Trial: 8358980
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing of methotrexate (15 mg)
Trial: 3526734
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 120 mg/day (6 X 20 mg)
Trial: 29863691
Drug: Cellex (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellex (0.1 mg daily for 10 days)
Trial: 27167103
Drug: ivabradine and
RxNorm normalized name: carvedilol and ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine and beta-blockers
Trial: 27167103
Drug: beta-blockers alone
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blockers alone
Trial: 25862567
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Trial: 18037940
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT) and stem cell support
Trial: 1723288
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (observation)
Trial: 18037940
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with CHUT
Trial: 12623421
Drug: Radiotherapy (involved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (involved field doses range from 40 to 48 Gy, median 44.5 Gy)
Trial: 12623421
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (radiotherapy followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, by six cycles)
Trial: 10390385
Drug: Tapering of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals
Trial: 30632847
Drug: Asparaginase treatment
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase treatment
Trial: 27555294
Drug: Concomitant dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant dexamethasone therapy
Trial: 22780999
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day ginseng
Trial: 22780999
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day ginseng
Trial: 22780999
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day ginseng
Trial: 19534023
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg/d for 2 months
Trial: 17024220
Drug: Postoperative steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative steroid drops
Trial: 17024220
Drug: Single sub‐tenon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single sub‐tenon injection of triamcinolone
Trial: 15042637
Drug: Caregiver skill‐building
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver skill‐building (CSB) treatment intervention
Trial: 3414729
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg phenylpropanolamine
Trial: 3414729
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg phenylpropanolamine plus 400 mg caffeine
Trial: 3414729
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg phenylpropanolamine
Trial: 31982647
Drug: Behavioral activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral activation intervention administered in a 16-week freshman orientation course
Trial: 25514515
Drug: iTBS (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTBS (intermittent theta burst stimulation) applied daily over dPMCright during a four-day hand training program using mirror training (MT) for 20 minutes daily.
Trial: 25514515
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation (control group CG) during the same four-day hand training program using mirror training (MT) for 20 minutes daily.
Trial: 21564047
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Trial: 21564047
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Trial: 9810030
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata gum resin 300 mg thrice daily for 6 weeks
Trial: 9810030
Drug: Lactose 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose 300 mg thrice daily for 6 weeks (Control)
Trial: 2667311
Drug: urapidil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil (60 mg twice daily)
Trial: 2667311
Drug: captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: captopril (25 mg twice daily)
Trial: 31454356
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs) provided monthly during screenings.
Trial: 15246460
Drug: 2-deoxyglucose (2-DG)
RxNorm normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxyglucose (2-DG) 40 mg/kg, i.v.
Trial: 30482135
Drug: Warm fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm fluid bolus (500 mL of Ringer's acetate at 38°C)
Trial: 30482135
Drug: Cold fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold fluid bolus (500 mL of Ringer's acetate at 22°C)